연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2877. Double-stranded RNA induction asa potential dynamic biomarkerfor DNA-demethylating agents
Kang M, Kharbash R, Byun JM, Jeon J, Ali AA, Ku D, Yoon J, Ku Y, Sohn J, Lee SV, Shin DY, Koh Y, Yoon SS, Hong J, Kim Y
Mol Ther Nucleic Acids. 2022 Jul 21;29:370-383
Link
2876. Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival
Lee HI, Lee J, Lee JH, Wu HG, Kim JH, Kim Y, Eom KY
JAMA Otolaryngol Head Neck Surg
. 2022 Sep 29;e222561. doi: 10.1001/jamaoto.2022.2561. Online ahead of print
Link
2875. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam 1, Muralidhar Beeram 2, Erika Hamilton 3, Do-Youn Oh 4, Diana L Hanna 5, Yoon-Koo Kang 6, Elena Elimova 7, Jorge Chaves 8, Rachel Goodwin 9, Jeeyun Lee 10, Lisle Nabell 11, Sun Young Rha 12, Jose Mayordomo 13, Anthony El-Khoueiry 14, Shubham Pant 15, Kanwal Raghav 15, Jin Won Kim 16, Amita Patnaik 2, Todd Gray 17, Rupert Davies 17, Mark A Ozog 17, Joseph Woolery 17, Keun-Wook Lee 16
Lancet Oncol. 2022 Dec;23(12):1558-1570
Link
2874. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Hedy L Kindler 1, Pascal Hammel 2, Michele Reni 3, Eric Van Cutsem 4, Teresa Macarulla 5, Michael J Hall 6, Joon Oh Park 7, Daniel Hochhauser 8, Dirk Arnold 9, Do-Youn Oh 10, Anke Reinacher-Schick 11, Giampaolo Tortora 12, Hana Algül 13, Eileen M O'Reilly 14, Sonal Bordia 15, David McGuinness 16, Karen Cui 17, Gershon Y Locker 17, Talia Golan 18
J Clin Oncol. 2022 Dec 1;40(34):3929-3939.
Link
2873. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
D V T Catenacci 1, Y-K Kang 2, H H Yoon 3, B Y Shim 4, S T Kim 5, D-Y Oh 6, A I Spira 7, S V Ulahannan 8, E J Avery 9, P M Boland 10, J Chao 11, H C Chung 12, F Gardner 13, S J Klempner 14, K-W Lee 15, S C Oh 16, J Peguero 17, M B Sonbol 18, L Shen 19, M Moehler 20, J Sun 21, D Li 21, M K Rosales 21, H Park 22
ESMO Open. 2022 Oct;7(5):100563
Link
2872. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
M Maio 1, P A Ascierto 2, L Manzyuk 3, D Motola-Kuba 4, N Penel 5, P A Cassier 6, G M Bariani 7, A De Jesus Acosta 8, T Doi 9, F Longo 10, W H Miller 11, D-Y Oh 12, M Gottfried 13, L Xu 14, F Jin 14, K Norwood 14, A Marabelle 15
Ann Oncol. 2022 Sep;33(9):929-938.
Link
2871. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study
Caroline Even 1, Jean-Pierre Delord 2, Katharine A Price 3, Kazuhiko Nakagawa 4, Do-Youn Oh 5, Matthew Burge 6, Hyun C Chung 7, Toshihiko Doi 8, Marwan Fakih 9, Shunji Takahashi 10, Lili Yao 11, Fan Jin 11, Kevin Norwood 11, Aaron R Hansen 12
Eur J Cancer. 2022 Aug;171:259-268. doi: 10.1016/j.ejca.2022.05.007. Epub 2022 Jun 28.
Link
2870. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
Yuichiro Doki 1, Makoto Ueno 2, Chih-Hung Hsu 3, Do-Youn Oh 4, Keunchil Park 5, Noboru Yamamoto 6, Tatsuya Ioka 7, Hiroki Hara 8, Manabu Hayama 9, Masahiro Nii 9, Keiko Komuro 9, Mariko Sugimoto 9, Makoto Tahara 10
Cancer Med. 2022 Jul;11(13):2550-2560. doi: 10.1002/cam4.4593. Epub 2022 May 24.
Link
2869. Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study
Michele Maio 1, Mayur M Amonkar 2, Josephine M Norquist 3, Paolo A Ascierto 4, Ludmila Manzyuk 5, Daniel Motola-Kuba 6, Nicolas Penel 7, Philippe A Cassier 8, Giovanni M Bariani 9, Ana De Jesus Acosta 10, Toshihiko Doi 11, Federico Longo 12, Wilson H Miller Jr 13, Do-Youn Oh 14, Maya Gottfried 15, Ruixue Wang 16, Kevin Norwood 17, Aurelien Marabelle 18
Eur J Cancer. 2022 Jul;169:188-197. doi: 10.1016/j.ejca.2022.03.040. Epub 2022 May 16.
Link
2868. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Bum Jun Kim # 1, Hee-Jung Jee # 2, Sun Young Rha # 3 4 5, Hye Sook Han 6 7, Min-Hee Ryu 8, Se Hoon Park 9, Jong Gwang Kim 10, Woo Kyun Bae 11, Keun-Wook Lee 12, Do-Youn Oh 13 14, Ji-Hye Byun 15, Dong Sook Kim 16, Young Ju Suh 17, Hyonggin An 18, Dae Young Zang 19
Gastric Cancer. 2022 May;25(3):609-618.
Link